Optibrium, Intellegens and Medicines Discovery Catapult awarded funding to apply machine learning in drug discovery

Thursday 20 September 2018, Imperial War Museum Duxford.

Optibrium, a developer of software for drug discovery, has announced it has signed a collaboration agreement with Intellegens, a company developing novel artificial intelligence (AI) software.

Bridging the gap in big data with innovative deep learning solutions.

Intellegens has entered into a commercial collaboration with e-Therapeutics; the Oxford-based pioneer of Network-Driven Drug Discovery (NDD).

Intellegens has received funding from Cambridge Enterprise and local angel investor to further develop its algorithms and platform.

General intelligence is now what matters as technical specialists find themselves replaced

Intellegens, a provider of specialist Artificial Intelligence (AI) algorithms to the drug discovery and material design sectors, has been awarded an InnovateUK grant to develop an experimental platform to enable integration of its unique algorithms with specialist software and modelling pipelines.

A new method in artificial intelligence is taking on the challenge of making predictions from fragmentary data